Literature DB >> 10655737

[Effects of aging and hyperlipidemia on plasma osteopontin level].

M Takemoto1, K Tada, K Nakatsuka, Y Moriyama, H Kazui, K Yokote, T Matsumoto, Y Saito, S Mori.   

Abstract

In order to elucidate a possible mechanism for accelerated atherogenesis as well as enhanced vascular calcification observed during the normal aging process, we measured plasma osteopontin (OPN) levels and examined their relation to aging and certain disease parameters. In all cases examined, no significant relation was found between the plasma OPN level and age, body mass index, blood pressure, plasma levels of glucose and insulin, serum levels of creatinine, triglyceride, and high density lipoprotein cholesterol. On the other hand, a significant negative correlation was found between the plasma OPN level and serum total cholesterol concentration (n = 78, r = -0.355, p = 0.0014). The serum level of low density lipoprotein (LDL) cholesterol, calculated by the formula of Friedewald, also showed a significant negative correlation to the plasma OPN level (n = 78, r = -0.301, p = 0.0075). In cases without diabetes mellitus and hypertension, a significant positive correlation was found between the plasma OPN level and age (n = 22, r = 0.445, p = 0.0378). It is postulated that OPN plays a negative regulatory role in the development of vascular calcification. Therefore, the observed negative relationship between the plasma OPN level and the serum levels of total cholesterol and LDL cholesterol, suggests a possibility that hypercholesterolemia facilitates vascular calcification by suppressing OPN synthesis. On the other hand, in non-diabetic and normotensive cases, the positive relationship between the plasma OPN level and age may reflect a defense mechanism against age-related increase of vascular calcification.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10655737     DOI: 10.3143/geriatrics.36.799

Source DB:  PubMed          Journal:  Nihon Ronen Igakkai Zasshi        ISSN: 0300-9173


  5 in total

1.  NK-104, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, reduces osteopontin expression by rat aortic smooth muscle cells.

Authors:  M Takemoto; M Kitahara; K Yokote; S Asaumi; A Take; Y Saito; S Mori
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

Review 2.  An update on the pathogenesis of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Piero Portincasa
Journal:  Curr Opin Gastroenterol       Date:  2018-03       Impact factor: 3.287

3.  Elevated plasma osteopontin associated with gastric cancer development, invasion and survival.

Authors:  Chun-Ying Wu; Ming-Shiang Wu; En-Pei Chiang; Cheng-Chung Wu; Yi-Ju Chen; Chien-Jen Chen; Nai-Hui Chi; Gran-Hum Chen; Jaw-Town Lin
Journal:  Gut       Date:  2006-12-05       Impact factor: 23.059

4.  Osteopontin is associated with increased arterial stiffness in rheumatoid arthritis.

Authors:  Laura Bazzichi; Lorenzo Ghiadoni; Alessandra Rossi; Melania Bernardini; Mario Lanza; Francesca De Feo; Camillo Giacomelli; Ilaria Mencaroni; Katia Raimo; Marco Rossi; Anna Maria Mazzone; Stefano Taddei; Stefano Bombardieri
Journal:  Mol Med       Date:  2009-06-18       Impact factor: 6.354

5.  Osteopontin deficiency protects mice from cholesterol gallstone formation by reducing expression of intestinal NPC1L1.

Authors:  Jing Lin; Wei-Qing Shao; Qing-Zhi Chen; Wen-Wei Zhu; Lu Lu; Hu-Liang Jia; Jin-Hong Chen
Journal:  Mol Med Rep       Date:  2017-06-14       Impact factor: 2.952

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.